Basic Information
| Drug ID | DDPD01142 |
|
| Drug Name | Doxepin | |
| Molecular Weight | 279.3761 | |
| Molecular Formula | C19H21NO | |
| CAS Number | 1668-19-5 | |
| SMILES | [H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12 | |
| External Links | ||
| DRUGBANK | DB01142 | |
| T3DB | T3D2993 | |
| PubChem Compound | 667468 | |
| PDR | 1965 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 4.29 | - | 4.29 | - | Maslanka A. et al. 2011. J AOAC Int. |
| Boiling Point | 155.5 | ℃ | 154-157 | ℃ | Budavari S. 1996. The Merck Index. |
| Melting Point | 188.0 | ℃ | 185-191 | ℃ | 'MSDS' |
| Water Solubility | 31.6 | mg/L | 31.6 | mg/L | Yalkowsky S. et al. 1992. Aquasol Database of Aqueous Solubility. |
| pKa | 8.96 | - | 8.96 | - | Embil K. and Torosian G. 1982. J Pharm Sci. |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Reference |
|---|---|---|---|---|---|---|
| Bioavailability | 30.0 | % | 30 | % | PO, oral; | DRUGBANK | Bioavailability | 30.0 | % | 30±10 | % | PO, oral; | The Pharmacological Basis of Therapeutics |
| C Max | 27.3 | ng/ml | 8.8-45.8 | ng/ml | PO, oral; | DRUGBANK | C Max | 28.0 | ng/ml | 28±11 | ng/ml | PO, oral; Derivative; depression; | The Pharmacological Basis of Therapeutics | C Max | 39.0 | ng/ml | 39±19 | ng/ml | PO, oral; Derivative; depression; | The Pharmacological Basis of Therapeutics |
| T Max | 4.0 | h | 3.5 | h | PO, oral; | DRUGBANK | T Max | 0.75 | h | 0.5-1 | h | PO, oral; Derivative; depression; | The Pharmacological Basis of Therapeutics | T Max | 8.0 | h | 4-12 | h | PO, oral; Derivative; depression; | The Pharmacological Basis of Therapeutics |
| Clearance | 0.93 | L/h/kg | 0.93 | l/h/kg | Plasma clearance; Oral single dose; normal,healthy; | DRUGBANK | Clearance | 0.84 | L/h/kg | 14±3 | ml/min/kg | The Pharmacological Basis of Therapeutics | Clearance | 0.84 | L/h/kg | 14 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 20.0 | L/kg | 20.0 | L/kg | Apparent volume of distribution; | DRUGBANK | Volume of Distribution | 24.0 | L/kg | 24±7 | L/kg | Apparent volume of distribution; | The Pharmacological Basis of Therapeutics | Volume of Distribution | 12.0 | L/kg | 12 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 15.0 | h | 15 | h | elimination half-life; | DRUGBANK | Half-life | 18.0 | h | 18±5 | h | The Pharmacological Basis of Therapeutics | Half-life | 37.0 | h | 37±15 | h | Active metabolite; | The Pharmacological Basis of Therapeutics | Half-life | 15.0 | h | 15 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Toxicity LD50 | 180.0 | mg/kg | 180.0 | mg/kg | PO, oral; mouse; | DRUGBANK | Toxicity LD50 | 147.0 | mg/kg | 147.0 | mg/kg | PO, oral; Rattus, Rat; | DRUGBANK | Toxicity LD50 | 26.0 | mg/kg | 26.0 | mg/kg | intravenous injection, IV; mouse; | T3DB | Toxicity LD50 | 16.0 | mg/kg | 16.0 | mg/kg | intravenous injection, IV; Rattus, Rat; | T3DB |
| Eliminate Route | 0 | % | ~0 | % | Urinary excretion; Unchanged drug; | The Pharmacological Basis of Therapeutics |
| Protein Binding | 75.5 | % | 75.5 | % | DRUGBANK | Protein Binding | 82.0 | % | 82(75-89) | % | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for children | 3.0 | mg/kg/day | 3 | mg/kg/day | PO, oral | Doxepin Hydrochloride Capsules (10 mg, 25 mg, 50 mg, 75 mg, 100 mg) | doxepin hydrochloride | PDR |
| Max dose for adolescents | 100.0 | mg/day | 100 | mg/day | PO, oral | Doxepin Hydrochloride Capsules (10 mg, 25 mg, 50 mg, 75 mg, 100 mg) | doxepin hydrochloride | PDR |
| Max dose for adolescents | 3.0 | mg/kg/day | 3 | mg/kg/day | PO, oral | Doxepin Hydrochloride Capsules (10 mg, 25 mg, 50 mg, 75 mg, 100 mg) | doxepin hydrochloride | PDR |
| Max dose for adults | 300.0 | mg/day | 300 | mg/day | Capsule, PO, Oral;Liquid; | Doxepin Hydrochloride Capsules (10 mg, 25 mg, 50 mg, 75 mg, 100 mg) | doxepin hydrochloride | PDR |
| Max dose for adults | 6.0 | mg/day | 6 | mg/day | Tablet,PO，oral | Doxepin Hydrochloride Capsules (10 mg, 25 mg, 50 mg, 75 mg, 100 mg) | doxepin hydrochloride | PDR |
| Max dose for geriatric | 300.0 | mg/day | 300 | mg/day | Capsule, PO, Oral;Liquid; | Doxepin Hydrochloride Capsules (10 mg, 25 mg, 50 mg, 75 mg, 100 mg) | doxepin hydrochloride | PDR |
| Max dose for geriatric | 6.0 | mg/day | 6 | mg/day | Tablet,PO，oral | Doxepin Hydrochloride Capsules (10 mg, 25 mg, 50 mg, 75 mg, 100 mg) | doxepin hydrochloride | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1